QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
NASDAQ:ADAP

Adaptimmune Therapeutics - ADAP Stock Forecast, Price & News

$1.65
+0.01 (+0.61%)
(As of 02/7/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.62
$1.69
50-Day Range
$1.25
$2.17
52-Week Range
$1.01
$3.32
Volume
103,541 shs
Average Volume
367,378 shs
Market Capitalization
$270.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Adaptimmune Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
263.6% Upside
$6.00 Price Target
Short Interest
Healthy
1.87% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.33mentions of Adaptimmune Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$113,002 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.09) to ($0.78) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

455th out of 1,029 stocks

Biological Products, Except Diagnostic Industry

72nd out of 168 stocks

ADAP stock logo

About Adaptimmune Therapeutics (NASDAQ:ADAP) Stock

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Receive ADAP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ADAP Stock News Headlines

The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Expert Ratings for Adaptimmune Therapeutics
Verismo Therapeutics Expands Quality and Compliance Team
SVB Securities Reaffirms Their Hold Rating on ImmunoGen (IMGN)
ReCode Therapeutics Establishes Scientific Advisory Board
Why Adaptimmune Therapeutics Stock Is Glowing Green Today
See More Headlines
Receive ADAP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ADAP Company Calendar

Last Earnings
11/04/2021
Today
2/07/2023
Next Earnings (Estimated)
3/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADAP
Employees
494
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+263.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-158,090,000.00
Net Margins
-998.26%
Pretax Margin
-988.49%

Debt

Sales & Book Value

Annual Sales
$6.15 million
Book Value
$1.32 per share

Miscellaneous

Free Float
135,372,000
Market Cap
$270.32 million
Optionable
Optionable
Beta
2.23

Key Executives

  • Adrian RawcliffeAdrian Rawcliffe
    Chief Executive Officer & Director
  • William C. BertrandWilliam C. Bertrand
    Chief Operating Officer
  • Gavin Wood
    Chief Financial Officer
  • Joanna Brewer
    Chief Scientific Officer
  • Sharp Kerry
    Senior Vice President & General Counsel













ADAP Stock - Frequently Asked Questions

Should I buy or sell Adaptimmune Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADAP shares.
View ADAP analyst ratings
or view top-rated stocks.

What is Adaptimmune Therapeutics' stock price forecast for 2023?

5 brokerages have issued twelve-month price objectives for Adaptimmune Therapeutics' shares. Their ADAP share price forecasts range from $3.00 to $10.00. On average, they predict the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 263.6% from the stock's current price.
View analysts price targets for ADAP
or view top-rated stocks among Wall Street analysts.

How have ADAP shares performed in 2023?

Adaptimmune Therapeutics' stock was trading at $1.46 at the start of the year. Since then, ADAP stock has increased by 13.0% and is now trading at $1.65.
View the best growth stocks for 2023 here
.

Are investors shorting Adaptimmune Therapeutics?

Adaptimmune Therapeutics saw a decline in short interest in the month of January. As of January 15th, there was short interest totaling 2,710,000 shares, a decline of 8.1% from the December 31st total of 2,950,000 shares. Based on an average trading volume of 536,000 shares, the days-to-cover ratio is presently 5.1 days. Approximately 1.9% of the shares of the stock are sold short.
View Adaptimmune Therapeutics' Short Interest
.

When is Adaptimmune Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023.
View our ADAP earnings forecast
.

How were Adaptimmune Therapeutics' earnings last quarter?

Adaptimmune Therapeutics plc (NASDAQ:ADAP) announced its earnings results on Thursday, November, 4th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by $0.04. The biotechnology company had revenue of $1.20 million for the quarter, compared to analyst estimates of $1.20 million. Adaptimmune Therapeutics had a negative net margin of 998.26% and a negative trailing twelve-month return on equity of 112.16%. During the same quarter last year, the company posted ($0.23) EPS.

What is Adrian Rawcliffe's approval rating as Adaptimmune Therapeutics' CEO?

6 employees have rated Adaptimmune Therapeutics Chief Executive Officer Adrian Rawcliffe on Glassdoor.com. Adrian Rawcliffe has an approval rating of 100% among the company's employees. This puts Adrian Rawcliffe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Adaptimmune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CA (CA), Endologix (ELGX), Brainstorm Cell Therapeutics (BCLI), Second Sight Medical Products (EYES), Shopify (SHOP), Micron Technology (MU), BlackRock (BLK), Cara Therapeutics (CARA) and Chipotle Mexican Grill (CMG).

When did Adaptimmune Therapeutics IPO?

(ADAP) raised $150 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is Adaptimmune Therapeutics' stock symbol?

Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP."

Who are Adaptimmune Therapeutics' major shareholders?

Adaptimmune Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (10.48%), Key Client Fiduciary Advisors LLC (0.18%), Vigilare Wealth Management (0.02%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adrian Rawcliffe, Cintia Piccina, Elliot Norry, Gavin Wood, James Noble, John Lunger, Lawrence M Alleva, William C Bertrand Jr and William C Bertrand, Jr.
View institutional ownership trends
.

How do I buy shares of Adaptimmune Therapeutics?

Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adaptimmune Therapeutics' stock price today?

One share of ADAP stock can currently be purchased for approximately $1.65.

How much money does Adaptimmune Therapeutics make?

Adaptimmune Therapeutics (NASDAQ:ADAP) has a market capitalization of $270.32 million and generates $6.15 million in revenue each year. The biotechnology company earns $-158,090,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis.

How many employees does Adaptimmune Therapeutics have?

The company employs 494 workers across the globe.

How can I contact Adaptimmune Therapeutics?

Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The official website for the company is www.adaptimmune.com. The biotechnology company can be reached via phone at 441235430000, via email at ir@adaptimmune.com, or via fax at 44-12-3543-0001.

This page (NASDAQ:ADAP) was last updated on 2/7/2023 by MarketBeat.com Staff